1. 钟南山 中国 广州医科大学 中国工程院院士 Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium ..
2. Carole D,Mitnick 美国 Harvard Medicine School Low body mass index as a predictor of sputum culture conversion and treatment outcomes among patient..
3. Jae-Gook,Shin 韩国 Inje University Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effect..
4. Jan-Willem C,Alffenaar 澳大利亚 University of Sydney Drug Exposure and Susceptibility of Pyrazinamide Correlate with Treatment Response in Pyrazinamide-S..
5. Jan-Willem C,Alffenaar 澳大利亚 University of Sydney Correlation of drug exposure and bacterial susceptibility with treatment response for Mycobacterium ..
6. Huib A.M,Kerstjens 荷兰 University of Groningen Isoniazid and rifampicin exposure during treatment in drug-susceptible TB
7. Tjip S,van der Werf 荷兰 University of Groningen Isoniazid and rifampicin exposure during treatment in drug-susceptible TB
8. Jan-Willem C,Alffenaar 澳大利亚 University of Sydney Is there a need to optimise pyrazinamide doses in patients with tuberculosis? A systematic review
9. Giovanni Battista,Migliori 瑞士 World Health Organization Clinical standards for the management of adverse effects during treatment for TB
10. Keertan,Dheda 南非 University of Cape Town Clinical standards for the management of adverse effects during treatment for TB
11. Jennifer,Furin 美国 Harvard University Clinical standards for the management of adverse effects during treatment for TB
12. Anneke C,Hesseling 南非 University of Stellenbosch Clinical standards for the management of adverse effects during treatment for TB
13. Marais, Ben J. 澳大利亚 University of Sydney Clinical standards for the management of adverse effects during treatment for TB
14. Charles A,Peloquin 美国 University of Florida Clinical standards for the management of adverse effects during treatment for TB
15. Schaaf, H. Simon 南非 Stellenbosch University Clinical standards for the management of adverse effects during treatment for TB
16. Jan-Willem C,Alffenaar 澳大利亚 University of Sydney Clinical standards for the management of adverse effects during treatment for TB
17. Jae-Gook,Shin 韩国 Inje University Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: imp..
18. Jan-Willem C,Alffenaar 澳大利亚 University of Sydney Dried Blood Spot Sampling to Assess Rifampicin Exposure and Treatment Outcomes among Native and Non-..
19. Monica,Gandhi 美国 University of California-San Francisco Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in..
20. Jan-Willem C,Alffenaar 澳大利亚 University of Sydney Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in..